about
In Barrett's esophagus patients and Barrett's cell lines, ursodeoxycholic acid increases antioxidant expression and prevents DNA damage by bile acids.Prospective randomized trial of enoxaparin, pentoxifylline and ursodeoxycholic acid for prevention of radiation-induced liver toxicity.Parenteral nutrition-associated liver complications in children.Effects of long term hydrophilic bile acid therapy on in vitro contraction of gallbladder muscle strips in patients with cholesterol gallstones.The effect of ursodeoxycholic acid in liver functional restoration of patients with obstructive jaundice after endoscopic treatment: a prospective, randomized, and controlled study.Deoxycholic acid causes DNA damage while inducing apoptotic resistance through NF-κB activation in benign Barrett's epithelial cells.Metal Zn(II), Cu(II), Ni (II) complexes of ursodeoxycholic acid as putative anticancer agentsProphylaxis and treatment recommendations for sinusoidal obstruction syndrome in adult and pediatric patients undergoing hematopoietic stem cell transplant: a review of the literature.Substrate specificities of rat oatp1 and ntcp: implications for hepatic organic anion uptake.Specific bile acids inhibit hepatic fatty acid uptake in mice.Increased susceptibility of cholangiocytes to tumor necrosis factor-alpha cytotoxicity after bile duct ligation.Combined endoscopic and ursodeoxycholic acid treatment of biliary cast syndrome in a non-transplant patient.Biliary cast syndrome in an opium inhaler.Utilization of hepatoprotectants within the National Health Insurance in Taiwan.Ursodeoxycholic acid therapy in cystic fibrosis liver disease--a retrospective long-term follow-up case-control study.Liraglutide-related cholelithiasis.Sex differences in the hepatic cholesterol sensing mechanisms in mice.
P2860
Q33913295-BCF1C0F4-7D14-41B2-BDB1-FCCDC0F31706Q34506324-6AEC02EE-DFDA-4B8D-9846-79327D42F8CBQ34523863-0E3AD6E4-D38D-4EE9-B607-77742FCAA2E1Q34606068-9E64DA06-DB5D-4B82-BDA1-077E7012EFB3Q34993108-3D988F4A-0047-4F96-8B76-CA571646D79BQ35159625-7143D26C-5E7B-4453-BCCD-C2B804A90FAAQ35644328-37252B66-B181-40AD-91EE-156300122B8DQ38540846-51131700-5605-4E53-83BF-6D11153E43CFQ42168990-39DB9AB3-FF84-4A25-B414-8AE89A722C8CQ42326059-2243A1D6-9B10-436C-B0A5-FA5A26D266ECQ42438271-2C77D74A-C41E-4F2A-BB3E-CFECCEBB0F0CQ42555450-9F8F3974-5CDC-4726-964D-7C4AE5B86677Q42936451-2C1DF16E-5FDC-4D93-8834-38CC50FD5D0AQ44471247-C8F52A05-D0D1-4F4A-A8D4-2EDB17380A62Q47198958-4941608A-715F-4006-AD9D-C381B9C66B9DQ50161857-D0B9AFC8-9536-41DA-ABC6-368682B663CEQ51204823-4E815D59-EAA8-41B1-BB07-85E09C26F46B
P2860
description
2000 nî lūn-bûn
@nan
2000 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
name
Ursodeoxycholic acid therapy in hepatobiliary disease
@ast
Ursodeoxycholic acid therapy in hepatobiliary disease
@en
Ursodeoxycholic acid therapy in hepatobiliary disease
@nl
type
label
Ursodeoxycholic acid therapy in hepatobiliary disease
@ast
Ursodeoxycholic acid therapy in hepatobiliary disease
@en
Ursodeoxycholic acid therapy in hepatobiliary disease
@nl
prefLabel
Ursodeoxycholic acid therapy in hepatobiliary disease
@ast
Ursodeoxycholic acid therapy in hepatobiliary disease
@en
Ursodeoxycholic acid therapy in hepatobiliary disease
@nl
P1476
Ursodeoxycholic acid therapy in hepatobiliary disease
@en
P2093
K V Kowdley
P356
10.1016/S0002-9343(00)00318-1
P407
P577
2000-04-15T00:00:00Z